Clinical trials: Cerebral Cavernous Hemangioma
Cavernous Angioma, Familial, Cerebral Cavernous Malformations
Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins
Cerebral cavernous malformations (CCMs) are clusters of abnormal blood vessels in the brain and spine. CCMs can bleed and cause strokes, seizures, and headaches. In some patients, CCMs affect the blood brain barrier (BBB).
- Conditions
- Cavernous Angioma, Familial, Cerebral Cavernous Malformations, Cerebral Cavernous Hemangioma
- Trial name
- NCT01764451
- Testing
- Simvastatin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of New Mexico
Hemangioma
Topical Timolol Gel for the Treatment of Infantile Hemangiomas
We plan to conduct a study, to see how safe and effective timolol maleate 0.5% gel-forming solution is for infantile hemangiomas (IH) and the response of hemangiomas to timolol maleate 0.5% .
- Trial name
- NCT02145884
- Testing
- timolol maleate 0.5% gel
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Rady Children's Hospital, San Diego
Cerebral Cavernous Malformations
Treatments and Outcomes of Untreated Cerebral Cavernous Malformations in CHina.
This nationwide multicenter prospective cohort study will collect the treatment information and outcomes of the patients with previously untreated cavernous malformations (U-CMs) in China (at least 2000 patients from 20 centers).
- Trial name
- TOUCH (NCT03467295)
- Testing
- Surgery, Observation
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Cavernous Malformation, Cerebral
Daratumumab for Familial Cerebral Cavernous Malformations: A Single-Arm Safety and Efficacy Study
Cerebral cavernous malformation (CCM) is a common vascular abnormality of the brain, affecting 0.1%-0.5% of people. It often causes recurrent brain hemorrhages, epilepsy, and neurological impairments, with surgery being the main…
- Trial name
- CCM-DS01 (NCT07026604)
- Testing
- Daratumumab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Beijing Tiantan Hospital
Cerebral Cavernous Malformation
Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial
This phase I/II randomized, placebo-controlled, double-blinded, single-site clinical trial is designed to investigate the effect of a prolonged course of atorvastatin versus placebo on CCM lesional iron deposition assessed by…
- Trial name
- AT CASH EPOC (NCT02603328)
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Chicago
CADASIL, Cavernous Angioma
Biological Collection of the Rare Diseases of the Brain and Eye Vessels Cohort - 2
CERVCO is the French National Reference Centre for Rare Cerebrovascular and Retinal Diseases, accredited by the Ministry of Health since 2005.
- Conditions
- CADASIL, Cavernous Angioma, Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy, Small Vessel Disease
- Trial name
- B-MRVC2 (NCT07650110)
- Testing
- Biocollection, Neurological evaluation and Biocollection
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Infantile Hemangioma, Capillary Hemangioma
A Prospective Study on the Incidence and Related Risk Factors of Infantile Hemangioma in China
Infant hemangioma(IH) is the most common benign vascular tumor of infancy with the estimated incidence varies 1% to 12%.However, in China, the incidence of infant hemangioma and related epidemiological data remains unclear.
- Conditions
- Infantile Hemangioma, Capillary Hemangioma, Capillary Hemangiomas, Hemangioma, Capillary Infantile
- Trial name
- IH (NCT03173352)
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Zhujiang Hospital
CCM, Familial Cerebral Cavernous Malformation
Natural History of Familial Cerebral Cavernous Malformations: the CCM_Italia Cohort Study
Patients with symptomatic and asymptomatic familial cerebral cavernous malformation (fCCM) will be included. The goal of this observational study is to learn about the long-term evolution of this condition.
- Trial name
- CCM_Italia (NCT06983132)
- Testing
- Cerebral imaging (MRI) according to a dedicated protocol with central MRI reading, Determination of circulating biomarkers
- Where
- 6 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Cerebral Cavernous Malformation
Functional Magnetic Resonance Imaging (fMRI) Vascular Reactivity in Cerebral Cavernous Malformations (CCM)
The goal is to characterize vascular reactivity and cardiac pulsatility of normal appearing white matter in patients with CCM during hypercarbia/hypocarbia using quantitative real-time high-speed multi-echo fMRI to develop…
- Trial name
- NCT05298709
- Testing
- Hyperventilation and CO2 challenge
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of New Mexico
Hemorrhagic Stroke, Intracerebral, Cerebral Cavernous Malformation
CCM Blood Biomarker Validation Study
Cerebral cavernous malformations (CCMs), one of the most common microvascular malformations in the capillary beds of the brain, are susceptible to hemorrhagic stroke.
- Trial name
- NCT05148663
- Testing
- CCM Hemorrhagic Panel
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Texas Tech University Health Sciences Center, El Paso
Arteriovenous Malformations, Cavernous Angiomas
Influence of MMP on Brain AVM Hemorrhage
Brain vascular malformations, including arteriovenous malformations (AVM), cavernous malformations (CVM) and aneurysms, are a source of life-threatening risk of intracranial hemorrhage. The etiology and pathogenesis are unknown.
- Conditions
- Arteriovenous Malformations, Cavernous Angiomas, Brain Aneurysms
- Trial name
- NCT00783523
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of California, San Francisco
Cerebral Cavernous Malformation
The Symptomatic Cerebral Cavernous Malformation Trial of REC-994
This is a two-part, multi-center, randomized, double-blind, placebo-controlled study to investigate the safety, efficacy and pharmacokinetics of REC-994 (200 mg and 400 mg) compared to placebo in participants with symptomatic…
- Trial name
- SYCAMORE (NCT05085561)
- Testing
- REC-994
- Where
- 15 sites in United States
- Volunteers
- 62 people
- Sponsor
- Recursion Pharmaceuticals Inc.
Cavernous Angioma, Familial, Cerebral Cavernous Malformations
Modifiers of Disease Severity in Cerebral Cavernous Malformations
Cerebral cavernous malformations (CCMs) are clusters of abnormal blood vessels in the brain and spine. CCMs can bleed and cause strokes, seizures, and headaches.
- Conditions
- Cavernous Angioma, Familial, Cerebral Cavernous Malformations, Cerebral Cavernous Hemangioma
- Trial name
- NCT01764529
- Where
- 7 sites in United States
- Volunteers
- 789 people
- Sponsor
- University of California, San Francisco
Tumor, Brain, Arteriovenous Malformations
Functional Navigation in Surgery of Cerebral Tumors and Vascular Malformations
The purpose of the study is to assess accuracy, advantages of functional neuronavigation and calculate safe distance from motor areas to brain tumors and vascular malformations in image-guided surgery.
- Conditions
- Tumor, Brain, Arteriovenous Malformations, Cavernoma
- Trial name
- FUN (NCT05484219)
- Testing
- Functional navigation
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Sklifosovsky Institute of Emergency Care
Cerebral Cavernous Malformation, Intracerebral Hemorrhage
CoHOrt of Cerebral CavernOus maLformATion: multicEnter Prospective Observational Study
The aim of this prospective study is to reveal the natural history of symptomatic hemorrhage in adult patients with cerebral cavernous malformation with the goal of informing the treatment plan.
- Trial name
- CHOCOOATE (NCT02946866)
- Where
- 8 sites in South Korea
- Volunteers
- 228 people
- Sponsor
- Seoul National University Hospital
Cerebral Cavernous Malformation
Treat_CCM: Propranolol in Familial Cerebral Cavernous Malformation
Cerebral Cavernous Malformation (CCM) is a cerebrovascular disease which can be either congenital in origin or sporadic and is characterized by the presence of isolated or multiple CCM lesions, causing recurrent headache…
- Trial name
- Treat_CCM (NCT03589014)
- Testing
- Propranolol
- Where
- 6 sites in Italy
- Volunteers
- 71 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Cerebral Cavernous Malformation
Study to Establish Safety, Tolerability and Pharmacokinetics of NRL-1049 in Healthy Adult Participants Following Multiple-Dose Administration
This Phase 1, dose-escalation, double-blind, multiple ascending dose (MAD) study was designed to assess the safety and tolerability of NRL-1049 compared to placebo in healthy adult participants and to determine the maximum…
- Trial name
- NCT07908134
- Testing
- NRL-1049
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Neurelis, Inc.
Cavernous Malformation, Cerebral, Cavernous Angioma
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
Cerebral cavernous malformation (CCM)-related epilepsy (CRE) impairs the quality of life in patients with CCM. Patients could not always achieve seizure freedom after surgical resection of the lesion, suggesting an inadequate…
- Conditions
- Cavernous Malformation, Cerebral, Cavernous Angioma, Cavernous Hemangioma, Cavernous Hemangioma of Brain
- Trial name
- CRESS (NCT04076449)
- Where
- 2 sites in China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- yuanli Zhao
Cerebral Cavernous Malformations
Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation
This is a single center, randomized, trial that will enroll twenty (n=20) patients with a diagnosis of symptomatic cavernous malformations who are planned candidates for surgical resection by one of the investigators, and who…
- Trial name
- NCT03474614
- Testing
- Propranolol, DNA and RNA Analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
CCM, Cavernoma
CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness
Brain Cavernous Angiomas with Symptomatic Hemorrhage (CASH) are rare, but they exact a heavy burden of neurologic disability from recurrent bleeding, for which there is no proven therapy.
- Conditions
- CCM, Cavernoma, Cerebral Cavernous Malformation, Cerebral Cavernous Malformations 1
- Trial name
- NCT03652181
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- University of Chicago